Managing juvenile absence epilepsy in patients younger than 16 years calls for age-appropriate first-line therapy. The clinical protocol below addresses initial treatment for this specific age group.
Patient is younger than 16 years of age with juvenile absence epilepsy. Age is a primary factor in selecting and structuring the recommended antiepileptic regimen.
Treatment begins with monotherapy. A Level A antiepileptic drug is recommended as the starting point, with titration carried out over the initial weeks of therapy to reach an established therapeutic range.
Full agent selection, titration schedule, and monitoring parameters are in the complete protocol ↓Children (younger than 16 years).
Treatment should begin with monotherapy. Level A: ethosuximide (Zarontin), valproic acid.
View source ↗